Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

WASHINGTON NEWS

WASHINGTON NEWS The Food and Drug Administration has moved to place broad new restrictions on prescription drug advertising, including greater prominence and detail for adverse reactions and contraindications. The proposals eventually are expected to be subject to hearings before FDA. One of the issues splitting FDA and the drug industry in the new proposals is whether drug advertising should be considered as mainly educational in nature, or mainly promotional. The Pharmaceutical Manufacturers Association had no immediate official comment on the FDA's proposals, but PMA president C. Joseph Stetler told reporters that in his opinion the recommendations would result in a distortion of advertising principles. Medical articles, not ads, are the proper vehicle for comprehensive information on efficacy and side effects of drugs, he said. If FDA insists on making the proposals a part of its regulations, the PMA is expected to oppose them formally. Here is a summary http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

WASHINGTON NEWS

JAMA , Volume 200 (6) – May 8, 1967

Loading next page...
 
/lp/american-medical-association/washington-news-pvTgRfgdnB

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1967 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1967.03120190027004
Publisher site
See Article on Publisher Site

Abstract

The Food and Drug Administration has moved to place broad new restrictions on prescription drug advertising, including greater prominence and detail for adverse reactions and contraindications. The proposals eventually are expected to be subject to hearings before FDA. One of the issues splitting FDA and the drug industry in the new proposals is whether drug advertising should be considered as mainly educational in nature, or mainly promotional. The Pharmaceutical Manufacturers Association had no immediate official comment on the FDA's proposals, but PMA president C. Joseph Stetler told reporters that in his opinion the recommendations would result in a distortion of advertising principles. Medical articles, not ads, are the proper vehicle for comprehensive information on efficacy and side effects of drugs, he said. If FDA insists on making the proposals a part of its regulations, the PMA is expected to oppose them formally. Here is a summary

Journal

JAMAAmerican Medical Association

Published: May 8, 1967

There are no references for this article.